Our Team

Narin Ahmed, PharmD

VP, Head of Regulatory Affairs, BS

Narin Ahmed, PharmD

Narin Ahmed is the Vice President and Head of Regulatory Affairs at GentiBio.  Prior to joining the company, Narin was the Global Regulatory Lead for Abecma at Celgene/Bristol Myers Squibb. Her work leading the integrated global regulatory strategy helped bring Abecma, the first approved BCMA-targeted CAR-T cell therapy, to patients around the world including the US, EU, Canada, and Switzerland. Narin started her career in Regulatory Affairs at Novartis Oncology where she led the US regulatory strategy on various early and late phase drug development programs. Narin led the submission of the original Kymriah IND and guided the US regulatory program through to approval of Kymriah in 2017 (the first ever CAR-T cell therapy approval in the world). Aside from being on the team that brought Kymriah to approval, one of Narin’s most notable achievements during her time on the program was leading the preparations for the Oncologic Advisory Committee meeting, resulting in a unanimous vote by FDA’s panel of experts to recommend approval of Kymriah for the treatment of certain kinds of pediatric ALL. Narin holds a B.S. in Biopharmaceutical Sciences with a concentration in Genomics, earned a Pharm.D. degree from Temple University, and completed her post-doctoral fellowship at Rutgers University.